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Abstract: Background: Cancer patients experience multiple symptoms throughout the course of the
disease. We aimed to provide a comprehensive analysis of the symptom burden in patients with
advanced cancer at admission to specialist palliative care (PC) services and seven days later to
estimate the immediate impact of PC intervention. Patient and methods: The analysis was based on an
observational, prospective, multicenter study (named DEMETRA) conducted in Italy on new patients
accessing network specialist PC centers during the period May 2017–November 2017. The prevalence
and intensity of symptoms were assessed at baseline and after seven days using three tools including
the Edmonton Symptom Assessment System (ESAS). Results: Five PC centers recruited 865 cancer
patients. Thirty-three different symptoms were observed at the baseline, the most frequent being
asthenia (84.9%) and poor well-being (71%). The intensity of the most frequent symptoms according
to ESAS ranged from 5.5 for asthenia to 3.9 for nausea. The presence and intensity of physical
symptoms increased with increasing levels of anxiety and depression. After seven days, prevalence
of nausea and breathlessness as well as intensity of almost all symptoms significantly decreased.
Conclusions: The study confirmed the considerable symptom burden of patients with advanced cancer.
PC intervention has significantly reduced the severity of symptoms, despite the patients’ advanced
disease and short survival.
Keywords: cancer patients; palliative care; symptoms
1. Introduction
Palliative care (PC) is mainly addressed to the evaluation and treatment of physical, functional,
psychological, social, and spiritual symptoms throughout the course of chronic and progressive
diseases, especially in the advanced and terminal phases [1,2], with the aim of improving, or at least
preserving, the patients’ quality of life.
Most of the evidence in recent decades has been related to the treatment of symptoms in cancer
patients, at any stage of the disease and of whatever causal origin. In fact, symptoms may derive
from the primary disease or its secondary localizations, but also from cancer therapies and even
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from treatments aimed to control comorbidities or other symptoms such as pain [3–9]. Nausea and
vomiting, for instance, may be due to the localization of the tumor, to impaired gastric emptying or
delayed gastrointestinal transit, to antineoplastic agents or radiation therapy, or to opioids given to
relieve pain [10,11]. In the patient’s evaluation, the distinction of the symptom’s causal factors may be
irrelevant, but for the physician, understanding the pathogenetic mechanisms is fundamental to setting
up specific therapies according to the cause. Moreover, the prevalence and severity of symptoms vary
across the phases of illness [12]. Pain, nausea, and depression have been reported to be relatively
stable over the last six months of life, while dyspnea, drowsiness, poor well-being, lack of appetite,
and asthenia tend to increase in severity over time. In particular, the patient’s symptom burden changes
during the last days of life, when PC becomes the specific and often only therapeutic approach [13].
The management of this clinical picture—with some symptoms tending to disappear and others taking
their place—is a central and crucial issue in controlling patient suffering.
In previous studies, only selected aspects of these symptoms were considered. We therefore
carried out this analysis with the objective of providing a comprehensive evaluation of the symptom
burden in patients with advanced cancer from the moment of admission to a PC service. We estimated
the prevalence and intensity of symptoms, the number of symptoms experienced simultaneously,
their prevalence based on the primary tumor site, and the way by which the presence and severity
of anxiety and depression could modify the physical symptoms. Symptom prevalence and intensity
were reassessed after seven days to estimate the immediate impact of PC, also paying attention to the
influence of the care setting on the clinical expression of symptoms.
2. Methods
2.1. Study Design and Participants
The data included in this analysis were obtained from an observational, prospective, multicenter
study (named DEMETRA) aimed at outlining the profile of patients, families, care services, and clinical
features from the moment of admission to specialized PC centers. The general characteristics of
the DEMETRA study have been published elsewhere [14]. Given the considerable extension of the
collected information and the achieved results, the Scientific Committee decided to divide its contents
into separate publications, each deepening a specific theme.
Five Italian PC units based in Florence, Forlì, Lecco, Palermo, and Rome participated in the
study, which included a total of 1013 individuals suffering from various advanced chronic diseases.
The majority of patients were cancer patients (85.4%), treated in three different care settings: home,
hospice, and hospital. The present analysis of symptoms focused only on cancer patients given the
high prevalence of cancer among the studied population and the specificity of the clinical conditions
and symptoms associated with cancer compared to other advanced diseases.
The inclusion criteria for the DEMETRA study were new patients accessing the PC network
between May 2017 and November 2017; age ≥ 18 years; presence of a chronic and progressive illness
requiring palliative intervention; and written informed consent for study participation and personal
data processing. Patients who were already in the care of a PC network and those who could not
ensure regular follow-up were excluded.
Eligible patients were recruited over a six-month period (from May to November 2017).
Each patient was followed up for 12 months until November 2018.
The present study considered only 865 cancer patients out of 1013 recruited in the DEMETRA
study. The flowchart of patients evaluated in the present study is shown in Figure 1. Overall, 780
patients answered the Edmonton Symptom. Assessment (ESAS) questionnaire and were considered
for the intensity of symptoms at baseline, while 508 (65.1%) were also evaluated at day 7.
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Figure 1. Flowchart of patients included in the study. ESAS, Edmonton Symptom Assessment System. 
2.2. Data Collection 
Patient information collected in the DEMETRA study included sociodemographic data, primary 
tumor site, presence and sites of metastasis, number of concomitant diseases, care setting (hospice, 
home care or hospital), and symptoms [14]. Data were collected at the baseline visit (day 0) and after 
seven days (day 7) to assess the first impact of palliative treatments. 
Symptoms were assessed using three tools: (1) the interRAI-PC, an instrument evaluating a wide 
range of PC issues including items related to symptoms [15]; (2) a supplementary list of items to 
detect symptoms and clinical aspects that were not covered by the interRAI-PC including rattle, 
dysphagia, dysgeusia, neuropathic pain, bowel occlusion, liver, and kidney functional impairment, 
paresis, motor disorders, spinal cord compression, pleural effusion and intracranial hypertension; (3) 
ESAS, which estimates the prevalence of nine main symptoms (pain, asthenia, nausea, depression, 
anxiety, drowsiness, breathlessness, poor well-being, lack of appetite) and their intensity, measured 
with a numeric rating scale ranging from 0 to 10 [16,17]. 
2.3. Consent Procedure and Ethical Approval 
The DEMETRA study was approved by the Ethics Committee of the A.S.S.T. of Lecco (Lecco, 
Italy) on 1 December 2016 and subsequently by the institutional review boards of each participating 
center. Written informed consent for participation in the study and processing of personal data were 
collected from all recruited patients before any study-related activity was carried out. 
2.4. Statistical Analysis 
Categorical variables were summarized as absolute and relative frequencies, while continuous 
variables were reported using mean values with the corresponding standard deviation (SD). The 
differences in the prevalence of symptoms across levels of anxiety and depression were evaluated 
Figure 1. Flowchart of patients included in the study. ESAS, Edmonton Symptom Assessment System.
2.2. Data Collection
Patient information collected in the DEMETRA study included sociodemographic data, primary
tumor site, presence and sites of metastasis, number of concomitant diseases, care setting (hospice,
home care or hospital), and symptoms [14]. Data were collected at th baseline visit (day 0) and after
seven days (day 7) to assess th first impact of palliative treatments.
Symptoms were assessed using three tools: (1) the interRAI-PC, an instrument evaluating a
wide range of PC issues including items related to symptoms [15]; (2) a supplementary list of items
to detect symptoms an clinical aspects that w re not covered by the int rRAI-PC including rattle,
dysphagia, dysgeusia, neuropathic pain, bowel cclusion, liver, and kidney functional impairment,
paresis, motor isorders, spinal cord compression, pl ural effusion and intracranial hypert nsion;
(3) ESAS, which estimates t e prevalence of nine main symptoms (pain, asthenia, nause , depression,
anxiety, drowsiness, bre thlessness, poor well-being, lack f appetite) and their intensity, measured
wit a numeric rating scale ra ging from 0 to 10 [16,17].
2.3. Consent Procedure and Ethical Approval
The DEMETRA study was approved by the Ethics Committee of the A.S.S.T. of Lecco (Lecco,
Italy) on 1 December 2016 and subsequently by the institutional review boards of each participating
center. Written informed consent for participation in the study and processing personal data were
c llected from all recruited patients before any study-related activity was carried out.
2.4. Statistical Analysis
Categorical variables were summarized as absolute and relative frequencies, while continuous
variables were reported using mean values with the corresponding standard deviation (SD).
The differences in the prevalence of symptoms across levels of anxiety and depression were evaluated
using Pearson’s chi-squared test, while the Kruskal–Wallis rank-sum test was used to evaluate
differences in median symptom intensity between different levels of anxiety and depression. McNemar’s
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chi-squared test was used to evaluate differences in the prevalence of symptoms between day 0 and
day 7. To compare symptom intensity at day 0 and day 7, we applied the paired-samples Wilcoxon test.
All data were analyzed using the R software package (version 3.6.1/2019, R Foundation for Statistical
Computing, Vienna, Austria).
3. Results
The baseline characteristics of patients are summarized in Table 1. Fifty-two percent were women
and the mean age was 74 years. Fifty-five percent of patients were taken in charge at home. The most
frequent primary tumor sites were the digestive system, lung, urinary, and reproductive system.
About 80% of patients had metastases, the most frequent sites being the liver, lung, and bone.
Table 1. Demographic and clinical characteristics of the 865 study patients at baseline.
Characteristics Patients N (%)
Female 447 (51.7)













Digestive system 248 (28.7)










Other sites 442 (51.1)
Patients with concomitant diseases 486 (56.2)
SD, standard deviation.
Table 2 lists the 33 symptoms observed at baseline in decreasing order of prevalence. The most
frequent symptoms were asthenia, poor well-being, lack of appetite, drowsiness, pain, depression,
constipation, anxiety, breathlessness, and insomnia. More than half of the patients had six to twelve
simultaneous symptoms and one-tenth had 15 or more symptoms (Supplementary Table S1).
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Poor well-being 614 71.0












Dry mouth 257 29.7
Bloating/flatulence 188 21.7
Vomiting 176 20.4
Recent falls 160 18.5
Gastroesophageal reflux 151 17.5










Muscle cramps 36 4.2
Death rattle 31 3.6
Seizures 27 3.1
Myoclonus 14 1.6
The most frequent combinations of concomitant symptoms at baseline are shown in Supplementary
Table S2. These combinations often included asthenia, lack of appetite, drowsiness, and poor well-being,
all of which were present in 46% of patients, while three of these symptoms, variously combined,
occurred in over half of the patients. Supplementary Table S3 shows the prevalence of the main
symptoms observed at the baseline according to the primary tumor site. Breathlessness was mainly
frequent in lung cancer, pain in pancreatic cancer, anxiety, and drowsiness in breast cancer, and lack of
appetite in colorectal cancer.
Nine of the 10 most frequent symptoms were included in the ESAS questionnaire. This allowed
us to measure the intensity of these symptoms in the whole population and in symptomatic patients,
as shown in Table 3. Patients were defined as symptomatic if a score greater than zero was recorded
for that symptom. In the first group, the intensity ranged from 5.2 (asthenia) to 1.7 (nausea); in the
second, from 5.5 (asthenia) to 3.9 (nausea).
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Table 3. Intensity of the most frequent symptoms in 780 patients at baseline.
Symptoms
All Patients Symptomatic Patients
Mean Intensity (SD) a N Mean Intensity (SD) a
Asthenia 5.17 (2.53) 734 5.50 (2.25)
Poor well-being 3.98 (2.90) 614 5.05 (2.30)
Lack of appetite 3.93 (3.01) 610 5.03 (2.47)
Drowsiness 3.10 (2.85) 543 4.45 (2.37)
Pain 3.03 (2.78) 523 4.51 (2.19)
Depression 2.68 (2.87) 482 4.33 (2.48)
Anxiety 2.41 (2.70) 456 4.12 (2.33)
Breathlessness 2.10 (2.79) 423 3.43 (3.03)
Nausea 1.75 (2.49) 348 3.91 (2.33)
SD, standard deviation. a Measured using a numeric rating scale from 0 to 10.
In Table 4, the intensity of symptoms were compared in patients evaluable at both visits, on day 0
and day 7. After one week, the intensity decreased significantly for all symptoms with the exception
of anxiety, depression, and drowsiness. Among patients with severe symptom intensity at baseline
(score ≥ 6), we observed a reduction in intensity for all symptoms (Supplementary Table S4).
Table 4. Changes in intensity of the main symptoms from day 0 to day 7 in 508 patients.
Symptoms Intensity, Mean (SD) a
p Value b
Day 0 Day 7 Difference (Day 7–Day 0)
Asthenia 4.89 (2.59) 4.47 (2.52) −0.42 (2.37) <0.001
Poor well-being 3.81 (2.85) 3.4 (2.70) −0.35 (2.38) <0.001
Lack of appetite 3.61 (3.03) 3.19 (2.93) −0.43 (2.63) <0.001
Drowsiness 3.00 (2.74) 2.77 (2.60) −0.23 (2.48) NS
Pain 2.96 (2.66) 2.19 (2.27) −0.76 (2.15) <0.001
Depression 2.58 (2.85) 2.60 (2.74) 0.02 (2.33) NS
Anxiety 2.27 (2.63) 2.27 (2.57) 0.01 (2.34) NS
Breathlessness 1.92 (2.69) 1.56 (2.49) −0.36 (1.72) <0.001
Nausea 1.61 (2.35) 1.28 (2.12) −0.33 (1.87) <0.001
NS, not statistically significant. a Measured using a numeric rating scale from 0 to 10; b p value for difference
between day 7 and day 0.
The prevalence and intensity of the four main physical symptoms (pain, breathlessness, nausea,
and asthenia) significantly increased with increasing levels of anxiety and depression (Table 5). Anxiety
and depression were grouped in asymptomatic patients (intensity = 0), patients with mild to moderate
symptoms (score between 1 and 4), and patients with elevated symptoms (score between 5 and 10).
Table 5. Prevalence and intensity of four physical symptoms in 780 patients according to the intensity
of anxiety or depression.
Symptoms




p Value b(N = 324) (N = 279) (N = 177) (N = 298) (N = 274) (N = 208)
Asthenia N 294 270 170 269 264 202
% 90.7 96.8 96.0 <0.05 90.3 96.4 97.1 <0.01
Intensity 4.67 5.03 6.32 <0.001 4.34 4.34 6.58 <0.001
Pain N 198 197 128 188 187 148
% 61.1 70.6 72.3 <0.05 63.1% 68.2% 71.2 NS
Intensity 2.64 3.08 3.64 <0.001 2.79 2.96 3.45 <0.05
Breathlessness N 135 151 90 114 155 107
% 41.7 54.1 50.8 <0.05 38.3% 56.6% 51.4 <0.05
Intensity 1.70 2.30 2.50 <0.01 1.73 2.43 2.19 <0.001
Nausea N 117 137 94 96 137 115
% 36.1 49.1 53.1 <0.001 32.2 50.0 55.3 <0.001
Intensity 1.27 1.69 2.70 <0.001 1.05 1.76 2.72 <0.001
NS, not statistically significant. a Measured using a numeric rating scale from 0 to 10; b p value for difference across
levels of intensity of anxiety or depression.
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After one week, breathlessness was significantly reduced in patients treated at home, while
nausea was significantly reduced in those treated at home or in a hospice (Supplementary Table S5).
Anxiety and depression significantly increased in patients treated at home and in the hospital,
respectively. Pain significantly decreased in all care settings; anxiety only in patients treated in hospital;
breathlessness, poor well-being, lack of appetite, nausea, and asthenia in those treated at home; and
lack of appetite, nausea, and asthenia in those in hospital (Table 6).
Table 6. Changes in intensity of the main symptoms between day 0 and day 7 according to the setting
of care in 508 patients overall and in those symptomatic at baseline.
Symptoms Setting
All Patients Symptomatic Patients
Intensity a, Mean (SD) Intensity a, Mean (SD)
Day 0 Day 7 p Value b Day 0 Day 7 p Value b
Asthenia Home 4.81 (2.59) 4.57 (2.48) <0.05 5.15 (2.34) 4.80 (2.34) <0.01
Hospice 5.12 (2.52) 4.16 (2.45) <0.01 5.54 (2.12) 4.33 (2.40) <0.001
Hospital 5.00 (2.74) 4.25 (2.98) NS 5.64 (2.18) 4.08 (2.85) <0.01
p value c NS NS NS NS
Poor well-being Home 3.99 (2.79) 3.70 (2.70) <0.01 4.92 (2.24) 4.35 (2.46) <0.001
Hospice 3.28 (3.01) 2.84 (2.68) NS 4.79 (2.44) 3.37 (2.68) <0.001
Hospital 3.34 (2.88) 2.66 (2.45) NS 4.74 (2.25) 2.90 (2.45) <0.001
p value c <0.05 <0.01 NS <0.001
Lack of appetite Home 3.65 (3.00) 3.30 (2.86) <0.01 4.85 (2.47) 4.06 (2.70) <0.001
Hospice 3.99 (3.27) 3.10 (3.19) <0.01 5.40 (2.61) 3.68 (3.09) <0.001
Hospital 2.50 (2.51) 2.45 (2.86) NS 4.23 (1.80) 3.31 (2.75) NS
p value c <0.05 NS NS NS
Drowsiness Home 2.98 (2.68) 2.80 (2.55) NS 4.20 (2.23) 3.57 (2.43) <0.001
Hospice 3.00 (2.89) 2.90 (2.74) NS 4.31 (2.51) 3.69 (2.56) NS
Hospital 3.09 (2.96) 2.25 (2.71) NS 4.69 (2.39) 2.55 (2.85) <0.01
p value c NS NS NS NS
Pain Home 3.14 (2.63) 2.45 (2.29) <0.001 4.38 (2.06) 3.15 (2.17) <0.001
Hospice 2.08 (2.59) 1.42 (2.04) <0.01 4.24 (2.11) 2.64 (2.29) <0.001
Hospital 3.20 (2.74) 1.66 (2.07) <0.001 4.55 (2.11) 2.06 (2.22) <0.001
p value c <0.001 <0.001 NS <0.01
Depression Home 2.55 (2.82) 2.63 (2.78) NS 4.24 (2.45) 3.88 (2.60) <0.05
Hospice 3.32 (3.00) 2.89 (2.70) NS 4.55 (2.60) 3.61 (2.64) <0.05
Hospital 1.25 (2.25) 1.73 (2.42) NS 4.23 (2.13) 3.15 (2.54) NS
p value c <0.001 <0.05 NS NS
Anxiety Home 2.22 (2.61) 2.43 (2.65) NS 3.95 (2.30) 3.55 (2.50) <0.05
Hospice 2.47 (2.80) 2.04 (2.53) NS 4.05 (2.53) 2.71 (2.74) <0.001
Hospital 2.32 (2.52) 1.34 (1.57) <0.05 4.08 (1.98) 1.64 (1.66) <0.001
p value b NS <0.05 NS <0.001
Breathlessness Home 1.97 (2.65) 1.64 (2.50) <0.001 4.02 (2.48) 3.15 (2.72) <0.001
Hospice 1.75 (2.69) 1.38 (2.51) NS 4.47 (2.51) 3.25 (3.17) <0.05
Hospital 1.86 (3.01) 1.23 (2.41) NS 5.47 (2.59) 2.87 (3.42) <0.05
p value c NS NS NS NS
Nausea Home 1.86 (2.45) 1.59 (2.28) <0.01 3.70 (2.26) 2.82 (2.46) <0.001
Hospice 1.05 (2.02) 0.51 (1.43) <0.001 3.23 (2.36) 1.17 (1.84) <0.001
Hospital 0.66 (1.67) 0.32 (0.83) NS 3.62 (2.20) 0.62 (1.41) <0.05
p value c <0.001 <0.001 NS NS
NS, not statistically significant; SD, standard deviation. a Measured using a numeric rating scale from 0 to 10;
b p value for difference between day 7 and day 0; c p value for difference between care settings.
4. Discussion
This study evaluated the symptom burden in a cancer patient population during the last days
of life, at the time of admission to specialist PC. The decision to appraise only cancer patients was
prompted by the need for a clinically homogeneous population, but also by the high proportion of
cancer patients among those included in the DEMETRA study. In addition, as already reported [18,19],
a cancer patient’s average life expectancy is generally short at the time of admission to PC. The median
survival in our population was 29 days, and only about 65.1% of patients were evaluable after the
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first seven days. Due to the advanced phase of disease, PC health professionals had a short while
to reach their therapeutic goals, which were mainly oriented to alleviate symptoms. We sought to
evaluate whether and how the symptom profile of patients could be changed in a few days as a result
of PC intervention.
We observed the presence of many symptoms at the time of PC admission. Asthenia was the most
frequent, followed by poor well-being, lack of appetite, drowsiness, pain, depression, constipation,
anxiety, breathlessness, and sleep disorders, which were present in 40% to 70% of patients. The large
number of symptoms is characteristic of the advanced stage of cancer, as previously documented [20].
Furthermore, patients experienced a large number of symptoms simultaneously, as also previously
observed [9,21]. This is an important and underestimated clinical problem. For patients, the multitude
of symptoms is very distressing, while for physicians, treating all the symptoms is complex due to the
number of drugs needed, their potential toxicity, and the risk of drug-to-drug interactions. This makes
it necessary to decide which symptoms should be primarily treated, with which drugs, and what
results are expected. All these latter considerations represent important aspects that open a window
to future insights. In our study, frequent combinations of simultaneous symptoms nearly always
included asthenia, lack of appetite, drowsiness, and poor well-being, consistent with the findings of
others [22,23]. Such combinations entail a negative physical and psychological condition, with lack of
energy and interests and detachment from life.
The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also
reported elsewhere [24,25]. The association between specific tumor sites and cancer symptoms is clear,
even at advanced stages of the disease when widespread metastasis can dilute this specificity. Instead,
some symptoms such as pain and asthenia tend to occur in all tumors.
The intensity of symptoms ranged from 5.2 for asthenia to 1.7 for nausea in the overall population,
and from 5.5 for asthenia to 3.9 for nausea in symptomatic patients, showing analogies to earlier
observations [26,27]. Interestingly, the prevalence and intensity of physical symptoms such as pain,
breathlessness, nausea, and asthenia correlated with the presence and severity of anxiety and depression,
reflecting the integration between physical and mental suffering.
We also evaluated whether and to what extent PC treatments could change the symptom profile
of patients after one week. A week is a short period of time, but not for patients with terminal cancer.
Their life expectancy is very limited, and as a consequence, every therapeutic intervention must be
immediately effective. The results obtained in one week are therefore an important measure of the
clinical impact of PC. In our study, the prevalence of symptoms between day 0 and 7 was unchanged,
except for breathlessness and nausea, which tended to decrease significantly. Considering that the
clinical situation quickly worsens in advanced cancer, even the containment of a few symptoms
should be seen as positive. Conversely, symptom intensity was significantly reduced after one week
of treatment, with the exception of depression, anxiety, and drowsiness. In the whole population,
the severity of the symptoms significantly decreased on average by about one point (approximatively a
20–25% reduction in symptoms intensity). However, in the group with a severe intensity of symptoms
(>6 points), the difference after one week was on average 1.3–1.4 points, similarly close to a 25%
reduction in pain intensity. Pain intensity difference was 2.20 points and nausea intensity difference
was 2.44, both over 30%. The evaluation as a percentage of pain reduction appears to be more relevant
because it relates to the initial intensity value [28]. We believe, therefore, that the reduction in the
intensity of symptoms is an important clinical result, indicating the relief of suffering at such a highly
critical time.
Finally, changes in the prevalence and intensity of symptoms between days 0 and 7 were evaluated
in the three settings of care: home, hospice, and hospital. Some symptoms had a different initial
prevalence depending on the setting. Poor well-being, pain, and nausea were more frequent in
patients at home, while lack of appetite and depression prevailed in hospice patients. After one week,
the reduction of intensity was almost uniform for all symptoms, with negligible differences related to
the setting of care.
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The main strength of this study is that it provides a comprehensive analysis of various aspects
of the symptoms experienced by cancer patients in the final period of life. Its main limitation is the
impossibility of describing the treatments given for such symptoms and the subsequent clinical results
because the DEMETRA study protocol did not include the collection of these data. It is also important
to underline a further limitation. The comparison between day 0 and day 7 was only possible in
patients still alive, and therefore we cannot exclude the necessity of considering the possibility of the
presence of a selection bias and an overestimation of results.
5. Conclusions
The primary aim of this study was to define the clinical symptom profile of 865 patients with
advanced cancer from the moment they accessed PC services. The study confirmed that the number
and severity of symptoms in these patients was substantial. Multiple symptoms were frequently
present and many of them were perceived as severe. Our results make it clear that PC intervention
can significantly reduce the severity of symptoms, even at the advanced stages of cancer. This further
finding confirms the need for these patients to receive competent PC. In our opinion, such competence
concerns not only PC specialists, but also oncologists, general practitioners, and any other physicians
dealing with patients at an advanced stage of disease.
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in intensity of main symptoms between day 0 and day 7 in 508 patients with severe degree of intensity at baseline,
Table S5: Changes in symptom prevalence between day 0 and day 7 in 508 patients according to care setting.
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